Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

NEW YORK, NY / ACCESS Newswire / March 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and ...

Novo Nordisk ... of Novo Nordisk Inc. “With NovoCare Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy at a reduced ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

While Zepbound has a single main ingredient, CagriSema’s two components can’t be dissolved together, requiring them to be manufactured separately and then delivered with a dual-chambered pen. Novo’s ...

Smaller compounding pharmacies, which make drugs to fill prescriptions for individual patients and are primarily overseen by U.S. states, must immediately cease making copies of tirzepatide. The FDA ...

In making his ruling, Pittman wrote that "good cause exists for Novo Nordisk's intervention in this case under Federal Rule of Civil Procedure 24." The rule allows for intervention of a third ...

single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s ...

Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...

Novo Nordisk will offer its weight loss drug Wegovy ... NovoCare will also offer refill reminders and access to live support from a case manager at the company, among other patient support services.